×
Click if you have patients on Pushtronex® system and need information on transition to a new device
Peer and Patient Videos | Repatha® (evolocumab)
INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease.. READ MORE

    • For US healthcare professionals

    HEAR ABOUT THE ROLE OF REPATHA® FROM PEERS AND PATIENTS

    Insights About Repatha® From Fellow Healthcare Professionals

    Watch a Video on Dr. Richard Wright Discussing the Role of Repatha®(evolocumab)

    REPATHA® in Established CVD Patients

    Duration: 24:16 minutes

    Watch Dr. Richard Wright discuss the role of Repatha®, review the clinical efficacy and safety results from FOURIER, and how Repatha® can help real patients.

    Watch a Video on Dr. Richard Wright Reviewing the Efficacy and Safety Results of Repatha® (evolocumab)

    FOURIER Subanalysis: Patients With a Recent MI (<1 Year)

    Duration: 6:08 minutes

    Watch Dr. Richard Wright review the efficacy and safety results of Repatha®, including a FOURIER subanalysis of patients who suffered a myocardial infarction within 1 year prior to study enrollment.

    Watch a Video on Dr. Richard Wright Discussing In-Hospital Lipid Management with Repatha® (evolocumab)

    EVOPACS & EVACS: In-Hospital Lipid Management

    Duration: 6:19 minutes

    Watch Dr. Richard Wright discuss LDL-C lowering and initiation of Repatha®, including in patients hospitalized for ACS from the EVOPACS and EVACS clinical studies.

    Watch Dr. Konstantinos Koskinas and Dr Thorsten Leucker Discuss Early Initiation of LDL-C Lowering therapies in an Acute Setting

    Importance of Early Initiation of LDL-C Lowering Therapies in the Acute Setting

    Duration: 22:37 minutes

    Watch an expert interview, Dr. Konstantinos Koskinas and Dr. Thorsten Leucker discuss the critical role of Repatha® and initiation early after an MI in an acute setting.

    Watch Dr. Michael Davidson Explore a Patient Case Scenario for Risk for an MI or stroke

    Exam Room Discussion for Patients at Risk for an MI or Stroke

    Duration: 10:53 minutes

    Watch Dr. Michael Davidson explore a patient case scenario featuring a hypothetical 62-year-old patient with 2 prior episodes of MI who is at risk of another MI or stroke.

    See What Your Peers Are Saying About Repatha®

    Watch a Video on Dr. Shah's Experience Treating MI in Patients with ASCVD

    Identifying Patients Who Might Be Right for Repatha® (evolocumab)

    Duration: 5:14 minutes

    Hear Dr. Shah share her insights and experience treating myocardial infarctions (MI) in patients with atherosclerotic cardiovascular disease (ASVCD); Dr. Shah identifies patients who could benefit from Repatha® to lower LDL-C and the risk of another MI or stroke.

    Watch a Video on Dr. Shah Discussing the Importance of Treating Patients Following an MI

    Reduce the Risk of Another MI or Stroke After Adding Repatha®

    Duration: 1:00 minute

    Hear Dr. Shah discuss the urgent action needed to treat patients within the first year following an MI to reduce the risk of another MI or stroke. In the FOURIER Study, Repatha® + statin reduced the risk of MI by 27% for patients with established CVD. HR 0.73 (95% CI, 0.65 – 0.82). Not statistically significant.

    Watch a Video on Dr. Angueira-Serrano, Endocrinologist, Sharing the Accessibility and Affordability of Repatha® (evolocumab)

    Experiences With Access and Affordability for Patients

    Duration: 1:00 minute

    Dr. Angueira-Serrano, endocrinologist, shares how access to and affordability of Repatha® improved since it first launched and his experience with coverage and the Repatha® Co-Pay Card.

    Watch Dr. Turnbo Discuss How Repatha® (evolocumab) Can Help to Reduce Risk of MI and Stroke in ASCVD Patients

    Improving Care for ASCVD Patients With Repatha®

    Duration: 1:00 minute

    Dr. Turnbo, primary care physician, explains how he achieves treatment goals for patients who have had an MI, stroke, or other cardiovascular event, and how Repatha® can help.

    Watch a Video on Dr. Shah and Dr. Turnbo Sharing Their Experience With Using Repatha® (evolocumab)

    The Role of LDL-C Treatment for Patients With Established CVD

    Duration: 1:00 minute

    Dr. Shah and Dr. Turnbo share their experience with using Repatha® as a tool to reduce their patients LDL-C below 70 mg/dL.

    Watch Real Repatha® Patient Stories

    Watch Andy's Testimonial on the Convenience of Injecting Repatha® (evolocumab) at Home

    Patient Testimonial: Convenience of At-Home Repatha® Injections

    Duration: 0:49 Minutes

    “The fact that I can do an injection myself…
    is so convenient for me.”*

    *Individual results may vary.

    Watch a Video on Andy's Journey on Repatha® (evolocumab)

    Andy’s Story: Established CVD and Journey on Repatha®

    Duration: 5:03 minutes

    Andy was diagnosed in his 30s, and he always struggled to get his cholesterol down to an acceptable level despite eating healthy and exercise. After being on Repatha® for not even months, his LDL-C dropped from >100 to 26 mg/dL. In the FOURIER study, established CVD patients taking Repatha® + statin lowered LDL-C by 63% at 12 weeks.*

    *Individual results may vary.

    Watch a Video on Joe’s Experience of Lowering his LDL-C With Repatha® (evolocumab)

    Joe’s Story: LDL-C Lowering Experience With Repatha®

    Duration: 4:21 minutes

    Joe’s hereditary high LDL-C levels led to heart surgery and large lifestyle changes. After Joe went on Repatha®, he was very happy to see his LDL-C level on his blood report drop from 130 to 35 mg/dL.*

    *Individual results may vary.

    Watch a Repatha® (evolocumab) Co-pay Card Testimonial From Patient, Joe

    Co-Pay Card Testimonial: Lowering Out-of-Pocket Costs for Repatha®

    Duration: 0:55 minutes

    “The Repatha® Co-Pay Card was very useful because it made Repatha® more affordable for me.”*

    *Individual results may vary.

    ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease; LDL-C, low‐density lipoprotein cholesterol; MI, myocardial infarction; PCSK9, proprotein convertase subtilisin/kexin type 9.

    Important Safety Information

    • Contraindications: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
    • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
    • Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

      • From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

    • Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

      • Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

    • Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

    Indications

    Repatha® is indicated:

    • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease
    • as an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDLC)- lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

    Please see full Prescribing Information.

    Important Safety Information

    Back To Top